ライフサイエンスコーパス: noncancerous

1 ir gene-metabolites associations compared to noncancerous adjacent tissues.

2 tically increased in human HCC compared with noncancerous adjacent tissues.

3 sion: This is the first direct evidence that noncancerous, adult human livers harbor several types of

4 as a positive control (PC) and binds to both noncancerous and cancer cells through the HIV-derived TA

5 t PTEN signaling regulates infection of both noncancerous and cancerous cells by multiple intracellul

6 ere also found in epithelial and mesenchymal noncancerous and cancerous tissues and cell lines.

7 differential levels of cell proliferation in noncancerous and cancerous tissues correlated with a str

8 to be present in all cells tested in vitro, noncancerous and cancerous, including patient-derived tu

9 ected complexes were also tested against the noncancerous ARPE-19 (retinal pigment epithelial cells)

10 h which to discriminate prostate cancer from noncancerous benign disease depend on the type of benign

11 Compared with noncancerous biliary epithelial cells, the expression of

12 ncreased levels of miR-26a compared with the noncancerous biliary epithelial cells.

13 ancer cell lines but were less active in the noncancerous BJ-hTERT cells.

14 erous (LNCaP, C4-B, DU145, and PC-3) but not noncancerous (BPH-1) prostate epithelial cells by down-r

15 ific to cancer and do not generally occur in noncancerous breast disease.

16 consists of epithelial cultures derived from noncancerous breast tissue, treated with the chemical ca

17 ic diagnosis was cancerous, precancerous, or noncancerous but had the potential for local destruction

18 lines (HeLa, A2780, and A2780cisR) and on a noncancerous cell line (HFL-1).

19 ortantly, significantly less active toward a noncancerous cell line (MRC-5).

20 t cancer), DU145 (prostate cancer), or Vero (noncancerous cell line).

21 atives, which were screened in cancerous and noncancerous cell lines.

22 n assessed and compared with L1210 and human noncancerous cell lines.

23 drug-resistant colon cancer cell lines over noncancerous cell lines.

24 drug-resistant colon cancer cell lines over noncancerous cell lines.

25 cancerous cells (MCF-7 and MDA-MB-435) over noncancerous cells (HUVECs and MCF-10A).

26 presence of a vast excess of the respective noncancerous cells [NIH 3T3 cells, human embryonic kidne

27 and was about 40 times less toxic toward the noncancerous cells and 4-fold more toxic toward the Dox

28 HO-3867 exhibited minimal toxicity toward noncancerous cells and tissues but induced apoptosis in

29 ast cancer cells, with minimal uptake by the noncancerous cells compared to the linear peptide with t

30 s p53 transcription and selectively protects noncancerous cells from p53-dependent apoptosis.

31 However, the cytotoxicity toward noncancerous cells having typical membrane compositions,

32 asion-promoting factors and can also rely on noncancerous cells in the tumor microenvironment as an a

33 K signaling may serve integral functions for noncancerous cells in the tumor microenvironment.

34 e expressions of glycans in cancerous versus noncancerous cells of the same origin, this approach has

35 Noncancerous cells remained unaffected during this regim

36 ons, whether this methylation also occurs in noncancerous cells, and whether these epigenetic events

37 rostate cancer (PCa) specimens than adjacent noncancerous cells.

38 oliferation, without affecting the growth of noncancerous cells.

39 mor activity, while being less toxic against noncancerous cells.

40 er cells by apoptosis, with little effect on noncancerous cells.

41 mon liability of cancer drugs is toxicity to noncancerous cells.

42 ubsets to discriminate between cancerous and noncancerous cells.

43 uman cells have also been discriminated from noncancerous cells.

44 d the cancerous cells than the corresponding noncancerous cells.

45 s electronegative relative to the surface of noncancerous cells.

46 tosis and autophagy, with minimal effects on noncancerous cells.

47 and human papillomavirus "low-risk" types in noncancerous clinical outcomes.

48 In noncancerous colon tissues from patients with ulcerative

49 mechanism, E(2) influences the physiology of noncancerous colonocytes, resulting in fewer preneoplast

50 focused on evaluating the effects of E(2) in noncancerous colonocytes.

51 Here we examined tissues from noncancerous colons of ulcerative colitis patients to de

52 ause following hysterectomy/oophorectomy for noncancerous conditions; it is also commonly prescribed

53 lted in increased cancerous cell death while noncancerous control cells were unaffected.

54 stologically confirmed breast cancer and 406 noncancerous controls with information on both serum PCB

55 tectomy slides were annotated for cancer and noncancerous disease and coregistered to MR imaging with

56 Computer-identified features for each of the noncancerous disease categories (eg, benign prostatic hy

57 ocarcinoma and adjacent (normal or abnormal) noncancerous endometrium underwent successful clonal ana

58 eration of MCF-7 cells but not MCF-10 cells (noncancerous epithelial cells).

59 onfidently distinguish between cancerous and noncancerous epithelial prostate cells in vitro.

60 colorectal adenocarcinoma cell line and from noncancerous fetal lung tissue.

61 ypes (AUC = 0.70) compared with grouping all noncancerous findings together (AUC = 0.62).

62 nhance cell growth and increase migration of noncancerous HEK cells; indeed, both properties were alm

63 uld not be identified from the corresponding noncancerous hepatic tissues.

64 erived from transcriptional responses in the noncancerous host tissues as well as the developing tumo

65 enocarcinoma breast cell lines compared with noncancerous human breast epithelial cells.

66 ably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic ef

67 st 3-fold in all of the tumors compared with noncancerous kidney and contained known WT-related genes

68 lines (SK-MEL, KB, BT-549, SK-OV-3) and two noncancerous kidney cell lines (LLC-PK1 and Vero).

69 is and five Wilms' tumors were compared with noncancerous kidney tissues using microarrays containing

70 the highest expression change compared with noncancerous kidney was topoisomerase IIalpha.

71 The noncancerous lesions are equally distributed proximally

72 the incidence, latency, and histotype of two noncancerous lesions, hyperplastic alveolar nodules (ana

73 ues, including 77 pairs of HCCs and matching noncancerous liver and 22 normal livers, were analyzed f

74 theoretical possibility of injuring adjacent noncancerous liver cells, thereby restricting the liver'

75 rom an arterial source while the majority of noncancerous liver is supplied by the portal vein.

76 Host DNA extracted from fragments of noncancerous liver, collected during surgical resection

77 lite markers in 81 HCCs and 77 corresponding noncancerous livers as a measure of CIN.

78 Noncancerous livers demonstrated increased methylation i

79 ere significantly higher in the HCCs than in noncancerous livers in 18 of the 21 loci (P values range

80 a transgenic mice acquire both cancerous and noncancerous mammary lesions.

81 -MB-231) binding compared to when exposed to noncancerous (MCF10A and HUVEC) cells.

82 have stable populations of cancer-prone, but noncancerous, mutant cells awaiting further genetic hits

83 ized to undergo either RF or IRE ablation of noncancerous normal liver.

84 somes but was also observed with exosomes of noncancerous origin.

85 ctively respiring Saos2 and HOS OS cells and noncancerous osteoblastic hFOB cells.

86 ne NuTu-19 and for cell toxicity against the noncancerous ovarian tissue cell line OVepi.

87 SPARC expression in fibroblasts from noncancerous pancreatic tissue was augmented by cocultur

88 ) synthase, resulting in Gb(3) expression in noncancerous polarized epithelial cells lacking endogeno

89 igh levels in cancer cells relative to their noncancerous precursors.

90 as been expanded to study both cancerous and noncancerous prostate cells.

91 tant induced anchorage-independent growth of noncancerous prostate epithelial cells (RWPE-1).

92 iting enzyme) was expressed in cancerous and noncancerous prostate glands.

93 ine and other biofluids, but also cancer and noncancerous prostate tissue, has resulted in new biomar

94 compared to samples of hormone-naive PCa and noncancerous prostate tissue.

95 ress higher levels of this truncated AR than noncancerous prostate tissue.

96 methylation in 30 DNA samples isolated from noncancerous prostate tissue.

97 xin family, gene expression profiles from 21 noncancerous prostate tissues, 16 clinically localized P

98 cers, 91 metastatic prostate cancers, and 25 noncancerous prostate tissues.

99 ted between the clinically localized PCa and noncancerous prostate tissues.

100 ples examined and detectable in only 2 of 52 noncancerous prostate tissues.

101 BKV is present at a much lower frequency in noncancerous prostates.

102 pression in cancerous LNCaP cells but not in noncancerous PWR-1E and RWPE-1 cells (all human prostate

103 st cancer cells and compared with release in noncancerous RAW 264.7 macrophage cells.

104 this study, we stably expressed E6 and E7 in noncancerous RPE1 cells and analyzed the specific mitoti

105 es with their power in predicting cancer vs. noncancerous samples.

106 basal cell or squamous cell carcinomas from noncancerous skin abnormalities, such as actinic keratos

107 RNA expression profiles of 482 cancerous and noncancerous specimens from radical resection of 241 pat

108 RNA-sequencing approach to gastric tumor and noncancerous specimens, generating 680 million informati

109 ns arising during DNA replication in normal, noncancerous stem cells.

110 s, but little is known about how they affect noncancerous stromal cells within the tumor microenviron

111 Clustering also separated cancerous from noncancerous tissue and cell lines from in vivo tissues

112 gests a high rate of premalignant changes in noncancerous tissue before the formation of a solitary t

113 ompositions that enhance cancer vs. adjacent noncancerous tissue classification across five different

114 analyzed the apoptotic profile for tumor and noncancerous tissue for each biopsy specimen using IHC.

115 pairs of DNA samples from colon cancers and noncancerous tissue with topoisomerase I and then amplif

116 samples revealed that, compared with that in noncancerous tissue, L1 expression is specifically enhan

117 ncy, age-associated somatic TP53 mutation in noncancerous tissue.

118 primary and metastatic tumors compared with noncancerous tissue.

119 ines and 47 primary tumors and corresponding noncancerous tissues by a methylation-specific PCR.

120 RY2, CKI, CLOCK, and BMAL1) of cancerous and noncancerous tissues from 29 GC patients were investigat

121 lines, nine matched CRC tissues and adjacent noncancerous tissues using reverse transcription (RT)-PC

122 TVM expression in tumors and noncancerous tissues was assessed by qRT-PCR and was pro

123 oma tumor tissues, as compared with adjacent noncancerous tissues, by liquid chromatography/mass spec

124 In corresponding noncancerous tissues, hypermethylation in RAR-beta and F

125 Compared with noncancerous tissues, PC expression was greatly enhanced

126 f miR-26 expression, as compared with paired noncancerous tissues, which indicated that the level of

127 ata from 31 hepatocellular carcinomas and 19 noncancerous tissues.

128 compared by immunoblotting with the adjacent noncancerous tissues.

129 escalated doses may also increase injury to noncancerous tissues.

130 iver tumor tissues compared with the matched noncancerous tissues.

131 detected in HCC tumor tissues compared with noncancerous tissues.

132 tations in the nontumorous colonic tissue in noncancerous UC cases indicate genetic damage from expos

133 frequency of specific p53 mutated alleles in noncancerous UC colon tissue may confer susceptibility t

134 hways fails to enhance the classification of noncancerous vs. cancerous tissues and the prediction of